SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).

被引：9
|
作者：
Lowe, Elizabeth S.
Jayawardene, Deepthi
Penson, Richard T.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5598
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
    Penson, Richard T.
    Villalobos Valencia, Ricardo
    Cibula, David
    Colombo, Nicoletta
    Leath, Charles A., III
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo Hyun
    Madry, Radoslaw
    Hernandez, Carlos
    Mora, Paulo A. R.
    Ryu, Sang Young
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Barker, Laura
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1164 - +
  • [2] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
    Penson, R. T.
    Valencia, R. V.
    Cibula, D.
    Colombo, N.
    Ill, C. L.
    Bidzinski, M.
    Kim, J. W.
    Nam, J. H.
    Madry, R.
    Hernandez, C. H.
    Mora, P.
    Ryu, S. Y.
    Milenkova, T.
    Lowe, E.
    Barker, L.
    Scambia, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
  • [3] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
    Penson, Richard T.
    Valencia, Ricardo Villalobos
    Cibula, David
    Colombo, Nicoletta
    Leath, Charles A.
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo-Hyun
    Madry, Radoslaw
    Hernandez, Carlos Hernandez
    Mora, Paulo Alexandre Ribeiro
    Ryu, Sang Young
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Barker, Laura
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Poveda, A.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Lindemann, K.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez-Martin, A.
    Madry, R.
    Perez, M. J. Rubio
    Ledermann, J.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Skof, E.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
  • [5] Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1-and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer
    Penson, Richard
    Valencia, Ricardo Villalobos
    Colombo, Nicoletta
    Leath, Charles
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo-Hyun
    Madry, Radoslaw
    Hernandez, Carlos
    Mora, Paulo
    Ryu, Sang-Young
    Milenkova, Tsveta
    Lowe, Elizabeth
    Lukashchuk, Natalia
    McNamara, John
    Scambia, Giovanni
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S19 - S20
  • [6] Maintenance olaparib monotherapy for platinum-sensitive relapsed ovarian cancer in patients without a germline BRCA1/BRCA2 mutation: Secondary safety results from the phase IIIb OPINION study
    Colombo, Nicoletta
    Madry, Radoslaw
    Skof, Erik
    Weberpals, Johanne
    Blakeley, Chris
    Marshall, Helen
    Brickel, Neil
    Poveda, Andres
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S81 - S82
  • [7] Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
    Poveda Velasco, A. M.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Elstrand, M.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez Martin, A. J.
    Madry, R.
    Rubio Perez, M. J.
    Ledermann, J. A.
    Ozgoren, O.
    Barnicle, A.
    Marshall, H.
    Bashir, Z.
    Skof, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S790 - S790
  • [8] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
    Shu, Yamin
    Liu, Yanxin
    He, Xucheng
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
    Liu, Jihong
    Yin, Rutie
    Wu, Lingying
    Zhu, Jianqing
    Lou, Ge
    Wu, Xiaohua
    Zhou, Qi
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Wang, Jing
    Chen, Youguo
    Cheng, Ying
    Wang, Yueling
    Lu, Weiguo
    Li, Wei
    Ma, Xin
    Hsu, Kate
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 714 - 722
  • [10] POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
    Golan, Talia
    Oh, Do-Youn
    Reni, Michele
    Macarulla, Teresa Mercade
    Tortora, Giampaolo
    Hall, Michael J.
    Reinacher-Schick, Anke C.
    Borg, Christophe
    Hochhauser, Daniel
    Walter, Thomas
    Hochster, Howard S.
    Baker, Nigel
    Locker, Gershon Y.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345